JP2014513135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513135A5 JP2014513135A5 JP2014509488A JP2014509488A JP2014513135A5 JP 2014513135 A5 JP2014513135 A5 JP 2014513135A5 JP 2014509488 A JP2014509488 A JP 2014509488A JP 2014509488 A JP2014509488 A JP 2014509488A JP 2014513135 A5 JP2014513135 A5 JP 2014513135A5
- Authority
- JP
- Japan
- Prior art keywords
- cocreatate
- composition
- lipid
- cation
- divalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 52
- 150000002632 lipids Chemical class 0.000 claims 36
- 150000001768 cations Chemical class 0.000 claims 23
- 238000000034 method Methods 0.000 claims 16
- 229940126575 aminoglycoside Drugs 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 238000004220 aggregation Methods 0.000 claims 5
- 230000002776 aggregation Effects 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 4
- 235000010469 Glycine max Nutrition 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910021645 metal ion Inorganic materials 0.000 claims 4
- 125000002091 cationic group Chemical group 0.000 claims 3
- -1 cationic lipid Chemical class 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 229930182566 Gentamicin Natural products 0.000 claims 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 2
- 244000068988 Glycine max Species 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 229960004821 amikacin Drugs 0.000 claims 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 2
- 229910052788 barium Inorganic materials 0.000 claims 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 239000001110 calcium chloride Substances 0.000 claims 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 229960002518 gentamicin Drugs 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 1
- 229960003942 amphotericin b Drugs 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940125725 tranquilizer Drugs 0.000 claims 1
- 239000003204 tranquilizing agent Substances 0.000 claims 1
- 230000002936 tranquilizing effect Effects 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482996P | 2011-05-05 | 2011-05-05 | |
| US61/482,996 | 2011-05-05 | ||
| US201161534075P | 2011-09-13 | 2011-09-13 | |
| US61/534,075 | 2011-09-13 | ||
| US201161547325P | 2011-10-14 | 2011-10-14 | |
| US61/547,325 | 2011-10-14 | ||
| US201161570067P | 2011-12-13 | 2011-12-13 | |
| US61/570,067 | 2011-12-13 | ||
| US201261590531P | 2012-01-25 | 2012-01-25 | |
| US61/590,531 | 2012-01-25 | ||
| US201261608272P | 2012-03-08 | 2012-03-08 | |
| US61/608,272 | 2012-03-08 | ||
| US201261620656P | 2012-04-05 | 2012-04-05 | |
| US61/620,656 | 2012-04-05 | ||
| US201261636793P | 2012-04-23 | 2012-04-23 | |
| US61/636,793 | 2012-04-23 | ||
| PCT/US2012/036576 WO2012151517A1 (en) | 2011-05-05 | 2012-05-04 | Cochleate compositions and methods of making and using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018061681A Division JP2018138552A (ja) | 2011-05-05 | 2018-03-28 | コクリエート組成物およびその製造および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513135A JP2014513135A (ja) | 2014-05-29 |
| JP2014513135A5 true JP2014513135A5 (https=) | 2015-06-25 |
| JP6347743B2 JP6347743B2 (ja) | 2018-06-27 |
Family
ID=47108070
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509488A Active JP6347743B2 (ja) | 2011-05-05 | 2012-05-04 | コクリエート組成物およびその製造および使用方法 |
| JP2018061681A Pending JP2018138552A (ja) | 2011-05-05 | 2018-03-28 | コクリエート組成物およびその製造および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018061681A Pending JP2018138552A (ja) | 2011-05-05 | 2018-03-28 | コクリエート組成物およびその製造および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140220108A1 (https=) |
| EP (1) | EP2704688B1 (https=) |
| JP (2) | JP6347743B2 (https=) |
| AU (1) | AU2012250568B2 (https=) |
| CA (1) | CA2834788C (https=) |
| ES (1) | ES2741282T3 (https=) |
| WO (1) | WO2012151517A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2704688B1 (en) * | 2011-05-05 | 2019-07-10 | Matinas BioPharma Nanotechnologies, Inc. | Cochleate compositions and methods of making and using same |
| KR102115718B1 (ko) * | 2012-07-30 | 2020-05-28 | 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드 | 대두 포스파티딜세린으로 제조된 코클리에이트 |
| US20150147382A1 (en) * | 2013-09-23 | 2015-05-28 | Exir Nano Sina Company | Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same |
| CN104398745A (zh) * | 2014-12-07 | 2015-03-11 | 王月水 | 一种治疗颈肩腰腿痛、腰椎间盘突出症的中药药浴及其制备方法 |
| CA2978308C (en) | 2015-03-03 | 2024-02-13 | Matinas Biopharma Nanotechnologies, Inc. | Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent |
| AU2016252885B2 (en) * | 2015-04-22 | 2021-05-20 | Matinas Biopharma Nanotechnologies, Inc. | Compositions and methods for treating mycobacteria infections and lung disease |
| CA2987798A1 (en) * | 2015-06-18 | 2016-12-22 | Matinas Biopharma Nanotechnologies, Inc. | Compositions and methods for treating inflammatory disease or conditions |
| WO2017205550A1 (en) * | 2016-05-24 | 2017-11-30 | Matinas Biopharma Nanotechnologies, Inc. | Immunogenic cochleates and methods of use |
| CA3027668A1 (en) * | 2016-07-12 | 2018-01-18 | Matinas Biopharma Nanotechnologies, Inc. | Encochleated antifungal compounds for central nervous system delivery and treatment of cryptococcus infections |
| CA3076336A1 (en) * | 2017-09-20 | 2019-03-28 | Atopic Medical, LLC | Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa |
| KR101989789B1 (ko) * | 2017-11-30 | 2019-06-18 | (주) 에이치엔에이파마켐 | 포스파티딜세린/음이온계면활성제/염화칼슘을 이용한 코킬레이트 |
| KR102019589B1 (ko) * | 2018-01-23 | 2019-11-04 | 가톨릭대학교 산학협력단 | 내이에서의 약물전달용 나노입자 |
| MX2022001871A (es) * | 2019-08-13 | 2022-03-11 | Matinas Biopharma Nanotechnologies Inc | Metodos de tratamiento de las infecciones por criptococo. |
| WO2024039733A1 (en) | 2022-08-16 | 2024-02-22 | Matinas Biopharma Nanotechnologies, Inc. | Methods of controlling lipid nanocrystal particle size and lipid nanocrystals produced by such methods |
| WO2024039729A1 (en) | 2022-08-16 | 2024-02-22 | Matinas Biopharma Nanotechnologies, Inc. | Antifungal agent encapsulated in a lipid nanocrystal for treating mucormycosis |
| WO2026010571A1 (en) * | 2024-07-05 | 2026-01-08 | Nanyang Technological University | Preparation of perfect, pure and uniform cochleates for drug delivery |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4078052A (en) | 1976-06-30 | 1978-03-07 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Large unilamellar vesicles (LUV) and method of preparing same |
| SE8501050D0 (sv) * | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
| GB8505882D0 (en) * | 1985-03-07 | 1985-04-11 | Central Blood Lab Authority | Purification of blood coagulation factor viii |
| US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
| US4643987A (en) | 1985-08-14 | 1987-02-17 | Eli Lilly And Company | Modified glycopeptides |
| US4639433A (en) | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| CA2031803C (en) | 1989-12-13 | 2001-05-29 | Ramakrishnan Nagarajan | Improvements in or relating to glycopeptide deriveratives |
| EP0786469B1 (en) | 1990-06-11 | 2006-03-01 | Gilead Sciences, Inc. | Methods of use of nucleic acid ligands |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| WO1993022336A1 (en) * | 1992-04-30 | 1993-11-11 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor viii complex |
| US5643574A (en) | 1993-10-04 | 1997-07-01 | Albany Medical College | Protein- or peptide-cochleate vaccines and methods of immunizing using the same |
| US5994318A (en) | 1993-10-04 | 1999-11-30 | Albany Medical College | Cochleate delivery vehicles |
| US5840707A (en) | 1993-10-04 | 1998-11-24 | Albany Medical College | Stabilizing and delivery means of biological molecules |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| MY128335A (en) | 1994-01-28 | 2007-01-31 | Lilly Co Eli | Glycopeptide antibiotic derivatives |
| JP2927225B2 (ja) | 1995-11-30 | 1999-07-28 | 日本電気株式会社 | 画像入力装置 |
| US6320029B1 (en) * | 1996-11-29 | 2001-11-20 | The American National Red Cross | Methods of production and use of liquid formulations of plasma proteins |
| EP0914094A4 (en) * | 1996-03-28 | 2000-03-01 | Univ Illinois | MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
| AU3111401A (en) * | 2000-01-24 | 2001-07-31 | Biodelivery Sciences, Inc. | New cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
| ES2386775T3 (es) | 2001-07-23 | 2012-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Procedimientos y composiciones para la inhibición mediada por ARNi de la expresión génica en mamíferos |
| US20030167490A1 (en) | 2001-11-26 | 2003-09-04 | Hunter Craig P. | Gene silencing by systemic RNA interference |
| US20030219473A1 (en) * | 2002-03-26 | 2003-11-27 | Leila Zarif | Cochleates made with purified soy phosphatidylserine |
| US8980310B2 (en) * | 2002-12-31 | 2015-03-17 | Bharat Serums and Vaccines, Ltd. | Non-pegylated long-circulating liposomes |
| US7351688B2 (en) * | 2003-02-05 | 2008-04-01 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein formulations |
| EP1631669A2 (en) | 2003-04-09 | 2006-03-08 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
| EP1624858B1 (en) | 2003-04-09 | 2018-06-06 | Rutgers, the State University of New Jersey | Novel encochleation methods |
| JP2007532573A (ja) * | 2004-04-09 | 2007-11-15 | バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド | ヌクレオチド−渦巻状組成物および使用の方法 |
| AU2005302255A1 (en) * | 2004-10-28 | 2006-05-11 | Alza Corporation | Lyophilized liposome formulations and method |
| CN101304757A (zh) * | 2005-06-29 | 2008-11-12 | 纽约州立大学研究基金会 | 免疫原性较低的蛋白质-脂质复合物的组合物和方法 |
| WO2007055789A2 (en) * | 2005-10-31 | 2007-05-18 | Neose Technologies, Inc. | Expression of soluble therapeutic proteins |
| HUE029994T2 (en) * | 2005-12-08 | 2017-04-28 | Insmed Inc | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| WO2008024389A2 (en) * | 2006-08-23 | 2008-02-28 | Biodelivery Sciences International, Inc. | Amphiphilic nucleotide cochleate compositions and methods of using the same |
| WO2009023355A2 (en) * | 2007-05-25 | 2009-02-19 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for reducing the toxicity of certain toxins |
| EP2704688B1 (en) * | 2011-05-05 | 2019-07-10 | Matinas BioPharma Nanotechnologies, Inc. | Cochleate compositions and methods of making and using same |
-
2012
- 2012-05-04 EP EP12779548.2A patent/EP2704688B1/en active Active
- 2012-05-04 CA CA2834788A patent/CA2834788C/en active Active
- 2012-05-04 WO PCT/US2012/036576 patent/WO2012151517A1/en not_active Ceased
- 2012-05-04 JP JP2014509488A patent/JP6347743B2/ja active Active
- 2012-05-04 US US14/115,770 patent/US20140220108A1/en not_active Abandoned
- 2012-05-04 AU AU2012250568A patent/AU2012250568B2/en active Active
- 2012-05-04 ES ES12779548T patent/ES2741282T3/es active Active
-
2018
- 2018-03-28 JP JP2018061681A patent/JP2018138552A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513135A5 (https=) | ||
| ES2831305T3 (es) | Liposomas que comprenden un aminoglucósido para el tratamiento de infecciones pulmonares | |
| JP6751424B2 (ja) | ダイズホスファチジルセリンで作られたコクリエート | |
| CN102292069B (zh) | 囊泡制剂 | |
| KR20150127580A (ko) | 지질 나노입자의 제조 방법 및 장치 | |
| Patel et al. | Liposome drug delivery system: a critic review | |
| CN103893123B (zh) | 一种脂质体-聚合物杂化纳米粒子及其制备方法和应用 | |
| EP3527201B1 (en) | Lipid nanoparticle film material composition | |
| CN101646462A (zh) | 药物转运控制用经肺给药脂质体 | |
| JP7681604B2 (ja) | 細胞膜を含むデバイスおよびその使用 | |
| Silva-Cázares et al. | Lipid-based nanoparticles for the therapeutic delivery of non-coding RNAs in breast cancer | |
| US20140271824A1 (en) | Acid Stable Liposomal Compositions And Methods For Producing The Same | |
| Zhu et al. | Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate | |
| CN102755292B (zh) | 一种含有二甲双胍囊泡类给药系统及其应用 | |
| Sankar et al. | Nanocochleate—A new approach in lipid drug delivery | |
| Yoshino et al. | Novel analytical method to evaluate the surface condition of polyethylene glycol-modified liposomes | |
| JP6986563B2 (ja) | ｂｃｌ−２を抑制するアンチセンスオリゴヌクレオチドの脂質ナノ粒子及びその調製方法 | |
| Lin et al. | Development and clinical applications of siRNA-encapsulated lipid nanoparticles in cancer | |
| Yeole et al. | A review on nanocochleate–A novel lipid based drug delivery system | |
| Veerapu et al. | Review on novel carrier system: liposomes and proliposomes | |
| Gol et al. | Nanocochleates: A novel approach for drug delivery | |
| Ashirov et al. | Engineering Liposomes for Neurodegenerative Diseases: Targeted Delivery and Regenerative Potential | |
| Vemuri et al. | Harnessing Liposomes for Advanced Gene Therapy: A Comprehensive Review | |
| Aghbolagh et al. | Liposomal Delivery for Targeting Macrophages | |
| EP4585212A1 (en) | Kit for manufacture of drug-containing nanoparticles and nanoparticle composition for drug delivery |